M
Michele Falda
Researcher at Sapienza University of Rome
Publications - 3
Citations - 752
Michele Falda is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Retinoic acid syndrome & Acute promyelocytic leukemia. The author has an hindex of 3, co-authored 3 publications receiving 746 citations.
Papers
More filters
Journal ArticleDOI
Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy
Franco Mandelli,Daniela Diverio,Giuseppe Avvisati,Anna Luciano,Tiziano Barbui,Carlo Bernasconi,Giorgio Broccia,Cerri R,Michele Falda,Giuseppe Fioritoni,Franco Leoni,Vincenzo Liso,Maria Concetta Petti,Francesco Rodeghiero,Giuseppe Saglio,M. L. Vegna,Giuseppe Visani,Ulrich Jehn,Roel Willemze,Petra Muus,Pier Giuseppe Pelicci,Andrea Biondi,Francesco Lo Coco +22 more
TL;DR: This study indicates that the AIDA protocol is a well-tolerated regimen that induces molecular remission in almost all patients with PML/RARα-positive APL and suggests that a remarkable cure rate can be obtained with this treatment.
Journal ArticleDOI
AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.
Giuseppe Avvisati,Lo Coco F,Daniela Diverio,Michele Falda,Felicetto Ferrara,Mario Lazzarino,Russo D,Maria Concetta Petti,Franco Mandelli +8 more
TL;DR: The results indicate that the AIDA protocol is highly effective in treating APL; after 3 consolidation courses, the majority of patients who achieved CR are RT-PCR- for the hybrid gene PML-RAR alpha; and the persistence of an RT- PCR positivity for the PML/RAR hybrid gene after3 consolidation courses is indicative of early relapse, thus these patients still require additional treatment.
Journal ArticleDOI
N-ras mutations in myeloid leukemias.
TL;DR: Investigation of the presence of mutations activating the N-ras gene in patients with acute myeloblastic leukemia at onset and in four patients with Ph' positive chronic myelogeneous leukemia either in chronic phase or in blast crisis suggests that a partial overlapping between initiation and progression factors could exist in naturally occurring tumors.